Womens Health Diagnostics Market By Type (Diagnostic Devices, Diagnostic Tests, Accessories and Consumables), By End User (Hospitals and Clinics, Diagnostic and Imaging Centers, Homecare, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

Womens Health Diagnostics Market

Women’s health diagnostics system improves the women’s health by screening, diagnosing, and monitoring the disease conditions, such as different types of cancer, infertility, and other diseases. The cervical cancer screening supports infertility, prenatal testing, and pregnancy care to breast and ovarian cancer diagnosis to managing bone health & diagnostics. Increase in need for the diagnostics of women’s health-related diseases is considered to be more susceptible to certain disorders, such as osteoporosis, menstrual disorders, cancer, and autoimmune diseases. The major diseases include, menopause, infertility, polycystic ovarian syndrome, and certain cancers, such as breast cancer and cervical cancer, as well as urological disorders. The medical diagnostics devices and tests help to improve the women’s health and accurate treatment against disease.

The key factor that drives the growth of market is rise in the prevalence of osteoarthritis, ovarian cancer, breast cancer, and cervical cancer. Breast cancer is the most commonly occurring cancer in women and the second most common cancer globally. Moreover, high cost of imaging & monitoring system and lack of skilled professionals are responsible for hampering the womens health diagnostics market growth. Moreover, due to miniaturization of ultrasound devices, untapped emerging economics in developing nations, such as Brazil, India, and UK, have been undergoing rapid changes in terms of healthcare investments and infrastructure, which create lucrative opportunities for key market players anticipated to boost the growth of market.

The womens health diagnostics industry is segmented on the basis of type, end user, and region. On the basis of type, the market is divided into diagnostic devices, diagnostic tests, and accessories and consumables. The devices segment is further segmented into biopsy devices and imaging and monitoring system. Imaging and monitoring systems segment is further segmented into ultrasound device, mammography systems & other. Ultrasound imaging systems is further sub segmented into OB/GYN ultrasound and breast ultrasound. Mammography systems are further categorized as analog mammography systems, digital mammography systems, and breast tomosynthesis system. The diagnostic tests segment is further categorized as breast cancer testing, cervical cancer testing, prenatal genetic screening and carrier testing, pregnancy and ovulation testing, and ovarian cancer testing. Breast cancer testing is further segmented into hormone receptor test, immunohistochemistry test, and other tests. Cervical cancer testing is bifurcated into PAP smear and HPV test. Prenatal genetic screening & carrier testing include tests for cystic fibrosis and other diseases. The pregnancy & ovulation testing segment is further bifurcated into lab-based pregnancy & ovulation testing, and home-based pregnancy & ovulation testing. Depending on end user, the market is categorized into hospitals and clinics, home care settings, diagnostic & imaging centers, and others. Based on region, womens health diagnostics industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By type, the market is divided into diagnostic devices, diagnostic tests, and accessories and consumables. The diagnostic tests segment was the highest contributor to the market in 2020. Increase in prevalence of various health-related disorders among women, such as cancer and infertility, growth in awareness about women’s health-related tests, high demand for point-of-care diagnostic testing, and development of numerous diagnostic & imaging centers drive the women’s health diagnostics market for tests.

By end user, the market is categorized into hospitals and clinics, home care settings, diagnostic & imaging centers, and others. The hospitals and clinics segment was the highest contributor to the market in 2020. The increase in incidence of breast and ovarian cancer has led to a significant rise in the number of hospitalization.

By region, North America constituted the highest womens health diagnostics market share in 2020, owing to numerous technological developments related to diagnosis of women and imaging techniques in this region. Asia-Pacific is projected to grow at the highest CAGR during the womens health diagnostics market forecast, owing to entry of novel tests and kits in the market, and rise in awareness about women’s health diagnostics technology.

KEY FINDINGS OF STUDY

By type, the diagnostic tests was the highest contributor to the market in 2020.

By end user, the hospitals & clinics segment dominated the market in 2020 and is expected to continue this trend during the forecast period.

On the basis of womens health diagnostics market analysis, North America garnered the largest revenue share in 2020; however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The women’s health diagnostics market was valued at $ 19,152.60 million in 2020, and is projected to reach $ 36,345.36 million by 2030, registering a CAGR of 6.9% from 2021 to 2030.

Women’s health diagnostics is a branch of medical science, which deals with the study, screening & diagnosis of a disease related to women health such as infertility, pregnancy, and different type of cancers. It will help to improve the women’s health & decrees the risk of disease. Different types of medical devices are available for screening and detection of diseases, including biopsy device, imaging & monitoring system, mammography system, and others, which detect cancer, remove blockages, and capture the images of internal organs help for screening & diagnosis of disease. The various types of treatments are also available for diagnosis includes the breast cancer testing, cervical cancer testing, prenatal genetic screening & carrier testing, pregnancy & ovulation testing & ovarian cancer testing. The use of tests for screening and detection of various disorders is necessary to prevent complications and improve quality of life. Health tests are vital for improving health and preventing and treating serious diseases.

Increase in prevalence of geriatric population of women’s across the globe suffering from different type of cancer, such as breast cancer, cervical cancer, and other, as well as technological advancements in diagnostic test & devices accelerate the market growth. In addition, rise in geriatric population globally boosts the market growth. High cost of imaging & monitoring system and lack of skilled professional impede the growth of the women’s health diagnostics market. Moreover, due to miniaturization of ultrasound devices, untapped emerging economics in developing nations, such as Brazil, India, and UK, have been undergoing rapid changes in terms of healthcare investments and infrastructure, which create lucrative opportunities for key market players.

The women’s health diagnostics market is segmented on the basis of type, end user, and region. On the basis of type, the market is divided into diagnostic devices, diagnostic tests, and accessories and consumables. The devices segment is further segmented into biopsy devices and imaging and monitoring system. Imaging and monitoring systems segment is further segmented into ultrasound device, mammography systems and other. Ultrasound imaging systems is further sub segmented into OB/GYN ultrasound and breast ultrasound. Mammography systems are further categorized as analog mammography systems, digital mammography systems, and breast tomosynthesis system. The diagnostic tests segment is further categorized as breast cancer testing, cervical cancer testing, prenatal genetic screening and carrier testing, pregnancy and ovulation testing, and ovarian cancer testing. Breast cancer testing is further segmented into hormone receptor test, immunohistochemistry test, and other tests. Cervical cancer testing is bifurcated into PAP smear and HPV test. Prenatal genetic screening & carrier testing include tests for cystic fibrosis and other diseases. The pregnancy & ovulation testing segment is further bifurcated into lab-based pregnancy & ovulation testing, and home-based pregnancy & ovulation testing. Depending on end user, the market is categorized into hospitals and clinics, home care settings, diagnostic & imaging centers, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

This report provides comprehensive competitive analysis and profiles of prominent market players ABBOTT, BD, Cardinal Health, Inc., F.Hoffmann-La Roche Ltd., General Electric Company, Hologic, Inc., Koninklijke Philips N.V., Quest Diagnostics Incorporated, Siemens Medical Solutions USA, Inc., and bioMérieux SA.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the womens health diagnostics industry, market segments, current trends, estimations, and dynamics of the womens health diagnostics market analysis from 2020 to 2030 to identify the prevailing womens health diagnostics market opportunity.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the womens health diagnostics market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global womens health diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

bioMérieux S

Scope of Womens Health Diagnostics Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Diagnostic Devices

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Diagnostic Tests

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Accessories and Consumables

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Hospitals and Clinics

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Diagnostic and Imaging Centers

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Homecare

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

5.5 Others

5.5.1 Key market trends, growth factors and opportunities

5.5.2 Market size and forecast, by region

5.5.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key trends and opportunities

6.2.2 North America Market size and forecast, by Type

6.2.3 North America Market size and forecast, by End User

6.2.4 North America Market size and forecast, by country

6.2.4.1 U.S.

6.2.4.1.1 Market size and forecast, by Type

6.2.4.1.2 Market size and forecast, by End User

6.2.4.2 Canada

6.2.4.2.1 Market size and forecast, by Type

6.2.4.2.2 Market size and forecast, by End User

6.2.4.3 Mexico

6.2.4.3.1 Market size and forecast, by Type

6.2.4.3.2 Market size and forecast, by End User

6.3 Europe

6.3.1 Key trends and opportunities

6.3.2 Europe Market size and forecast, by Type

6.3.3 Europe Market size and forecast, by End User

6.3.4 Europe Market size and forecast, by country

6.3.4.1 Germany

6.3.4.1.1 Market size and forecast, by Type

6.3.4.1.2 Market size and forecast, by End User

6.3.4.2 France

6.3.4.2.1 Market size and forecast, by Type

6.3.4.2.2 Market size and forecast, by End User

6.3.4.3 U.K.

6.3.4.3.1 Market size and forecast, by Type

6.3.4.3.2 Market size and forecast, by End User

6.3.4.4 Italy

6.3.4.4.1 Market size and forecast, by Type

6.3.4.4.2 Market size and forecast, by End User

6.3.4.5 Spain

6.3.4.5.1 Market size and forecast, by Type

6.3.4.5.2 Market size and forecast, by End User

6.3.4.6 Rest of Europe

6.3.4.6.1 Market size and forecast, by Type

6.3.4.6.2 Market size and forecast, by End User

6.4 Asia-Pacific

6.4.1 Key trends and opportunities

6.4.2 Asia-Pacific Market size and forecast, by Type

6.4.3 Asia-Pacific Market size and forecast, by End User

6.4.4 Asia-Pacific Market size and forecast, by country

6.4.4.1 Japan

6.4.4.1.1 Market size and forecast, by Type

6.4.4.1.2 Market size and forecast, by End User

6.4.4.2 China

6.4.4.2.1 Market size and forecast, by Type

6.4.4.2.2 Market size and forecast, by End User

6.4.4.3 Australia

6.4.4.3.1 Market size and forecast, by Type

6.4.4.3.2 Market size and forecast, by End User

6.4.4.4 India

6.4.4.4.1 Market size and forecast, by Type

6.4.4.4.2 Market size and forecast, by End User

6.4.4.5 South Korea

6.4.4.5.1 Market size and forecast, by Type

6.4.4.5.2 Market size and forecast, by End User

6.4.4.6 Rest of Asia-Pacific

6.4.4.6.1 Market size and forecast, by Type

6.4.4.6.2 Market size and forecast, by End User

6.5 LAMEA

6.5.1 Key trends and opportunities

6.5.2 LAMEA Market size and forecast, by Type

6.5.3 LAMEA Market size and forecast, by End User

6.5.4 LAMEA Market size and forecast, by country

6.5.4.1 Brazil

6.5.4.1.1 Market size and forecast, by Type

6.5.4.1.2 Market size and forecast, by End User

6.5.4.2 Saudi Arabia

6.5.4.2.1 Market size and forecast, by Type

6.5.4.2.2 Market size and forecast, by End User

6.5.4.3 South Africa

6.5.4.3.1 Market size and forecast, by Type

6.5.4.3.2 Market size and forecast, by End User

6.5.4.4 Rest of LAMEA

6.5.4.4.1 Market size and forecast, by Type

6.5.4.4.2 Market size and forecast, by End User

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Key developments

8.1 ABBOTT LABORATORIES

8.1.1 Company overview

8.1.2 Company snapshot

8.1.3 Operating business segments

8.1.4 Product portfolio

8.1.5 Business performance

8.1.6 Key strategic moves and developments

8.2 BECTON, DICKINSON AND COMPANY

8.2.1 Company overview

8.2.2 Company snapshot

8.2.3 Operating business segments

8.2.4 Product portfolio

8.2.5 Business performance

8.2.6 Key strategic moves and developments

8.3 CARDINAL HEALTH, INC.

8.3.1 Company overview

8.3.2 Company snapshot

8.3.3 Operating business segments

8.3.4 Product portfolio

8.3.5 Business performance

8.3.6 Key strategic moves and developments

8.4 F. HOFFMANN-LA ROCHE LTD.

8.4.1 Company overview

8.4.2 Company snapshot

8.4.3 Operating business segments

8.4.4 Product portfolio

8.4.5 Business performance

8.4.6 Key strategic moves and developments

8.5 GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY)

8.5.1 Company overview

8.5.2 Company snapshot

8.5.3 Operating business segments

8.5.4 Product portfolio

8.5.5 Business performance

8.5.6 Key strategic moves and developments

8.6 HOLOGIC, INC.

8.6.1 Company overview

8.6.2 Company snapshot

8.6.3 Operating business segments

8.6.4 Product portfolio

8.6.5 Business performance

8.6.6 Key strategic moves and developments

8.7 KONINKLIJKE PHILIPS N.V. (PHILIPS HEALTHCARE)

8.7.1 Company overview

8.7.2 Company snapshot

8.7.3 Operating business segments

8.7.4 Product portfolio

8.7.5 Business performance

8.7.6 Key strategic moves and developments

8.8 QUEST DIAGNOSTICS INCORPORATED.

8.8.1 Company overview

8.8.2 Company snapshot

8.8.3 Operating business segments

8.8.4 Product portfolio

8.8.5 Business performance

8.8.6 Key strategic moves and developments

8.9 SIEMENS AKTIENGESELLSCHAFT

8.9.1 Company overview

8.9.2 Company snapshot

8.9.3 Operating business segments

8.9.4 Product portfolio

8.9.5 Business performance

8.9.6 Key strategic moves and developments

8.10 bioMérieux SA

8.10.1 Company overview

8.10.2 Company snapshot

8.10.3 Operating business segments

8.10.4 Product portfolio

8.10.5 Business performance

8.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2020-2030,($MILLION)

TABLE 2. WOMENS HEALTH DIAGNOSTICS MARKET REVENUE, FOR DIAGNOSTIC DEVICES, BY REGION , 2020-2030,($MILLION)

TABLE 3. WOMENS HEALTH DIAGNOSTICS MARKET DIAGNOSTIC DEVICES BY COUNTRY, 2020-2030,($MILLION)

TABLE 4. WOMENS HEALTH DIAGNOSTICS MARKET REVENUE, FOR DIAGNOSTIC TESTS, BY REGION , 2020-2030,($MILLION)

TABLE 5. WOMENS HEALTH DIAGNOSTICS MARKET DIAGNOSTIC TESTS BY COUNTRY, 2020-2030,($MILLION)

TABLE 6. WOMENS HEALTH DIAGNOSTICS MARKET REVENUE, FOR ACCESSORIES AND CONSUMABLES, BY REGION , 2020-2030,($MILLION)

TABLE 7. WOMENS HEALTH DIAGNOSTICS MARKET ACCESSORIES AND CONSUMABLES BY COUNTRY, 2020-2030,($MILLION)

TABLE 8. GLOBAL WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 9. WOMENS HEALTH DIAGNOSTICS MARKET REVENUE, FOR HOSPITALS AND CLINICS, BY REGION , 2020-2030,($MILLION)

TABLE 10. WOMENS HEALTH DIAGNOSTICS MARKET HOSPITALS AND CLINICS BY COUNTRY, 2020-2030,($MILLION)

TABLE 11. WOMENS HEALTH DIAGNOSTICS MARKET REVENUE, FOR DIAGNOSTIC AND IMAGING CENTERS, BY REGION , 2020-2030,($MILLION)

TABLE 12. WOMENS HEALTH DIAGNOSTICS MARKET DIAGNOSTIC AND IMAGING CENTERS BY COUNTRY, 2020-2030,($MILLION)

TABLE 13. WOMENS HEALTH DIAGNOSTICS MARKET REVENUE, FOR HOMECARE, BY REGION , 2020-2030,($MILLION)

TABLE 14. WOMENS HEALTH DIAGNOSTICS MARKET HOMECARE BY COUNTRY, 2020-2030,($MILLION)

TABLE 15. WOMENS HEALTH DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)

TABLE 16. WOMENS HEALTH DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)

TABLE 17. WOMENS HEALTH DIAGNOSTICS MARKET, BY REGION, 2020-2030,($MILLION)

TABLE 18. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2020-2030,($MILLION)

TABLE 19. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 20. NORTH AMERICA WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 21. U.S. WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 22. U.S. WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 23. CANADA WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 24. CANADA WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 25. MEXICO WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 26. MEXICO WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 27. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2020-2030,($MILLION)

TABLE 28. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 29. EUROPE WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 30. GERMANY WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 31. GERMANY WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 32. FRANCE WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 33. FRANCE WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 34. U.K. WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 35. U.K. WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 36. ITALY WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 37. ITALY WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 38. SPAIN WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 39. SPAIN WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 40. REST OF EUROPE WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 41. REST OF EUROPE WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 42. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2020-2030,($MILLION)

TABLE 43. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 44. ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 45. JAPAN WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 46. JAPAN WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 47. CHINA WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 48. CHINA WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 49. AUSTRALIA WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 50. AUSTRALIA WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 51. INDIA WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 52. INDIA WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 53. SOUTH KOREA WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 54. SOUTH KOREA WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 55. REST OF ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 56. REST OF ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 57. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, BY TYPE, 2020-2030,($MILLION)

TABLE 58. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)

TABLE 59. LAMEA WOMENS HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 60. BRAZIL WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 61. BRAZIL WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 62. SAUDI ARABIA WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 63. SAUDI ARABIA WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 64. SOUTH AFRICA WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 65. SOUTH AFRICA WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 66. REST OF LAMEA WOMENS HEALTH DIAGNOSTICS MARKET BY TYPE 2020-2030,($MILLION)

TABLE 67. REST OF LAMEA WOMENS HEALTH DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)

TABLE 68.ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 69.ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 70.ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 71.ABBOTT LABORATORIES: NET SALES,

TABLE 72.ABBOTT LABORATORIES: KEY STRATERGIES

TABLE 73.BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT

TABLE 74.BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS

TABLE 75.BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO

TABLE 76.BECTON, DICKINSON AND COMPANY: NET SALES,

TABLE 77.BECTON, DICKINSON AND COMPANY: KEY STRATERGIES

TABLE 78.CARDINAL HEALTH, INC.: COMPANY SNAPSHOT

TABLE 79.CARDINAL HEALTH, INC.: OPERATING SEGMENTS

TABLE 80.CARDINAL HEALTH, INC.: PRODUCT PORTFOLIO

TABLE 81.CARDINAL HEALTH, INC.: NET SALES,

TABLE 82.CARDINAL HEALTH, INC.: KEY STRATERGIES

TABLE 83.F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 84.F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS

TABLE 85.F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 86.F. HOFFMANN-LA ROCHE LTD.: NET SALES,

TABLE 87.F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES

TABLE 88.GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY): COMPANY SNAPSHOT

TABLE 89.GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY): OPERATING SEGMENTS

TABLE 90.GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY): PRODUCT PORTFOLIO

TABLE 91.GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY): NET SALES,

TABLE 92.GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY): KEY STRATERGIES

TABLE 93.HOLOGIC, INC.: COMPANY SNAPSHOT

TABLE 94.HOLOGIC, INC.: OPERATING SEGMENTS

TABLE 95.HOLOGIC, INC.: PRODUCT PORTFOLIO

TABLE 96.HOLOGIC, INC.: NET SALES,

TABLE 97.HOLOGIC, INC.: KEY STRATERGIES

TABLE 98.KONINKLIJKE PHILIPS N.V. (PHILIPS HEALTHCARE): COMPANY SNAPSHOT

TABLE 99.KONINKLIJKE PHILIPS N.V. (PHILIPS HEALTHCARE): OPERATING SEGMENTS

TABLE 100.KONINKLIJKE PHILIPS N.V. (PHILIPS HEALTHCARE): PRODUCT PORTFOLIO

TABLE 101.KONINKLIJKE PHILIPS N.V. (PHILIPS HEALTHCARE): NET SALES,

TABLE 102.KONINKLIJKE PHILIPS N.V. (PHILIPS HEALTHCARE): KEY STRATERGIES

TABLE 103.QUEST DIAGNOSTICS INCORPORATED.: COMPANY SNAPSHOT

TABLE 104.QUEST DIAGNOSTICS INCORPORATED.: OPERATING SEGMENTS

TABLE 105.QUEST DIAGNOSTICS INCORPORATED.: PRODUCT PORTFOLIO

TABLE 106.QUEST DIAGNOSTICS INCORPORATED.: NET SALES,

TABLE 107.QUEST DIAGNOSTICS INCORPORATED.: KEY STRATERGIES

TABLE 108.SIEMENS AKTIENGESELLSCHAFT: COMPANY SNAPSHOT

TABLE 109.SIEMENS AKTIENGESELLSCHAFT: OPERATING SEGMENTS

TABLE 110.SIEMENS AKTIENGESELLSCHAFT: PRODUCT PORTFOLIO

TABLE 111.SIEMENS AKTIENGESELLSCHAFT: NET SALES,

TABLE 112.SIEMENS AKTIENGESELLSCHAFT: KEY STRATERGIES

TABLE 113.BIOMÉRIEUX SA: COMPANY SNAPSHOT

TABLE 114.BIOMÉRIEUX SA: OPERATING SEGMENTS

TABLE 115.BIOMÉRIEUX SA: PRODUCT PORTFOLIO

TABLE 116.BIOMÉRIEUX SA: NET SALES,

TABLE 117.BIOMÉRIEUX SA: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.WOMENS HEALTH DIAGNOSTICS MARKET SEGMENTATION

FIGURE 2.WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030

FIGURE 3.WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.WOMENS HEALTH DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.WOMENS HEALTH DIAGNOSTICS MARKET,BY TYPE,2020(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC DEVICES WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC TESTS WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ACCESSORIES AND CONSUMABLES WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 16.WOMENS HEALTH DIAGNOSTICS MARKET,BY END USER,2020(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AND CLINICS WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC AND IMAGING CENTERS WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOMECARE WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030(%)

FIGURE 21.WOMENS HEALTH DIAGNOSTICS MARKET BY REGION,2020

FIGURE 22.U.S. WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 23.CANADA WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 24.MEXICO WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 25.GERMANY WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 26.FRANCE WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 27.U.K. WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 28.ITALY WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 29.SPAIN WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 30.REST OF EUROPE WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 31.JAPAN WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 32.CHINA WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 33.AUSTRALIA WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 34.INDIA WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 35.SOUTH KOREA WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 36.REST OF ASIA-PACIFIC WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 37.BRAZIL WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 38.SAUDI ARABIA WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 39.SOUTH AFRICA WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 40.REST OF LAMEA WOMENS HEALTH DIAGNOSTICS MARKET,2020-2030($MILLION)

FIGURE 41. TOP WINNING STRATEGIES, BY YEAR

FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 45.COMPETITIVE DASHBOARD

FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 47.ABBOTT LABORATORIES.: NET SALES ,($MILLION)

FIGURE 48.BECTON, DICKINSON AND COMPANY.: NET SALES ,($MILLION)

FIGURE 49.CARDINAL HEALTH, INC..: NET SALES ,($MILLION)

FIGURE 50.F. HOFFMANN-LA ROCHE LTD..: NET SALES ,($MILLION)

FIGURE 51.GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY).: NET SALES ,($MILLION)

FIGURE 52.HOLOGIC, INC..: NET SALES ,($MILLION)

FIGURE 53.KONINKLIJKE PHILIPS N.V. (PHILIPS HEALTHCARE).: NET SALES ,($MILLION)

FIGURE 54.QUEST DIAGNOSTICS INCORPORATED..: NET SALES ,($MILLION)

FIGURE 55.SIEMENS AKTIENGESELLSCHAFT.: NET SALES ,($MILLION)

FIGURE 56.BIOMÉRIEUX SA.: NET SALES ,($MILLION